基于生物信息学分析SLC19A3基因在乳腺癌中的表达意义及蟾毒灵的干预研究

Expression and clinical significance of SLC19A3 in breast cancer and effects of Bufalin on the expression of SLC19A3: analysis based on the data-mining from bioinformatics

目的分析可溶性载体SLC19A3基因在乳腺癌中的表达及临床意义,并探讨蟾毒灵(Bufalin)对乳腺癌细胞中SLC19A3基因的干预作用。方法检索Oncomine和GEO数据库中从建库至今有关乳腺癌和Bufalin干预乳腺癌的数据集,对所获取的数据资料进行数据挖掘,分析SLC19A3基因在乳腺癌组织和正常乳腺组织中的表达情况,及其与预后的关系。同时分析Bufalin对乳腺癌细胞中SLC19A3基因表达水平的影响,并结合文献资料综合分析。结果对Oncomine数据库中共收集的9项关于乳腺癌和乳腺正常组织SLC19A3基因有差异表达的研究数据集进行分析,发现乳腺癌组织中SLC19A3基因的表达明显高于乳腺正常组织,差异有统计学意义(P<0.05)。通过生存分析发现低表达SLC19A3基因的乳腺癌患者无病生存期明显短于高表达者,高表达患者的预后更好(P<0.05)。通过挖掘GEO数据库中的数据集GSE85871发现Bufalin能够上调乳腺癌细胞SLC19A3基因的表达(P<0.01)。结论 SLC19A3基因在乳腺癌组织中呈现低表达,并与乳腺癌患者的预后相关,该基因可能是Bufalin干预乳腺癌细胞的一个新靶点。

Objective To analyze the expression and its clinical significance of SLC19 A3 gene in breast cancer and to explore the effects of Bufalin on the expression of SLC19 A3 in breast cancer cells. Methods The datasets about breast cancer and effects of Bufalin on breast cancer cell were retrieved from Oncomine and GEO database, and the datasets were deeply mined and analyzed with literature. SLC19 A3 m RNA expression between normal group and breast cancer group as well as correlation with prognosis were analyzed. Meanwhile, the effect of Bufalin on the expression level of SLC19 A3 gene in breast cancer cells was also analyzed. Results The expression of SLC19 A3 gene in breast cancer tissues was significantly higher than that of breast normal tissues through mining and analyzing the 9 datasets about SLC19 A3 gene in breast carcinoma from Oncomine database（P〈0.05）. Survival analysis showed that the disease-free survival of breast cancer patients with higher expression of SLC19 A3 gene was significantly better than the patients with lower expression of SLC19 A3, and the prognosis of patients with high expression of SLC19 A3 gene was better（P〈0.05）. Finally, the m RNA expression of SLC19 A3 gene was up-regulated by Bufalin in the datasets of GSE85871 through mining the GEO database（P〈0.01）. Conclusion SLC19 A3 gene is under-expressed in breast cancer and its expression level is related to the prognosis of breast cancer, which may be a new target of effects of Bufalin on breast cancer cells.